TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Incidence of clinically recognized peri- and post-operative atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Who Received the Dual Gonorrhea/Chlamydia Testing
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Safety and tolerability of TT-034
Endpoint domain: Adverse events/effects
Primary endpoint: Effectiveness of Nuberol Forte
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Safety of Nuberol Forte
Endpoint domain: Adverse events/effects
Primary endpoint: Blood Glucose Nadir
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Frequency of Dose-limiting Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: desflurane consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of participants with acceptable noninvasive intracranial pressure measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Change from baseline in peak oxygen consumption (peak VO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Microbial profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of veliparib/TMZ combination
Endpoint domain: Adverse events/effects
Primary endpoint: safety of TRC150094
Endpoint domain: Adverse events/effects
Primary endpoint: Concentrations of Antibodies Against Hepatitis B (Anti-HB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentrations of Antibodies Against Diphtheria (Anti-D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentrations of Antibodies Against Tetanus (Anti-T)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentrations of Anti-polyribosyl Ribitol Phosphate Antibodies (Anti-PRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentrations of Anti-Bordetella Pertussis Toxin Antibodies (Anti-BPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Cough Symptom
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Fever Symptom
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerable dose (MTD) of bortezomib
Endpoint domain: Adverse events/effects
Primary endpoint: Specific toxicities of bortezomib
Endpoint domain: Adverse events/effects
Primary endpoint: Dose limiting toxicity (DLT) of bortezomib
Endpoint domain: Adverse events/effects
Primary endpoint: BOLD MRI signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Food intake (kcal)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sensitivity of the 3D Confusion Assessment Method
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Specificity of the 3D Confusion Assessment Method
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Total Heavy Drinking Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change on Hamilton Depression Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Clinician Assisted Rating Scale for Mania (CARS-M) Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microbiological Success (Eradication of Baseline Pathogens)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: success rate of minimally invasive techniques
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mortality rate of acute biliary pancreatitis
Endpoint domain: Mortality/survival
Primary endpoint: Evidence of Clinically Definite Mastitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of Major Bleeding Events (MBEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of secondary causes of bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: neointima coverage percentage of stent strut
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intramyocellular lipid content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Intramyocellular lipid composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Exercise treadmill time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LV function by echocardiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of LV pressure development and decline (dP/dt and -dP/dt)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tumor standardized uptake value (SUV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Na+ stores in PD subjects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change in Na+ stores in PD subjects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Post-operative length of stay (nights)
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: End weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: meeting the postpartum weight goal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Mean Seated Systolic Blood Pressure (SBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety of Brolucizumab
Endpoint domain: Adverse events/effects
Primary endpoint: Anxiety level measured by STAI-Y
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anxiety level measured by APAIS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Eating Disorder Examination Questionnaire - Bulimic Symptoms Composite
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Early Neurological Deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Hb concentration levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change of biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of cerebral blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in lower airway secretions and tissues for selected airway remodeling mediators
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change of protein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Concentration of Proenkephalin-A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Creatinine Kinase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 24 Hour Urinary Kidney Injury Molecule 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in 24 Hour Urinary Neutrophil Gelatinase-associated Lipocalin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Parental Stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Stroke Literacy Improvement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: occurrence of hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients with ACR20 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from baseline in Coronary Flow Reserve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in Angina Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Plasma Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Concentration (AUC 0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Concentration (AUC 0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with elevated NT-proBNP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants with serious adverse events (SAEs) and adjudicated adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with liver function-related AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of dose-limiting toxicity incidents
Endpoint domain: Adverse events/effects
Primary endpoint: MTD of sorafenib tosylate and TH-302
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comprehensive complication index
Endpoint domain: Adverse events/effects
Primary endpoint: Skeletal muscle index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of consistency between the reports
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Measurement of Maximum Plasma Concentration [Cmax]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of Area Under the Curve [AUC]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects who experience any AEs that lead to study discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Good compliance to adjuvant therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Subject incidence of adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Clinically relevant changes in lab values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically relevant changes in ECGs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinically relevant changes in vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in averaged expiratory tidal volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Subjective improvement in floater symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Risk of solid organ transplant rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Physiological sleep signals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discontinuation Rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Increased notification of tuberculosis (TB)
Endpoint domain: Adverse events/effects
Primary endpoint: Post-pericardiotomy syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative effusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative atrial fibrillation incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Allograft function as determined by Schwartz GFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: PTSD Symptoms (PTSD Checklist-5)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Substance Use Disorder Symptoms (Cannabis Use Disorder Identification Test)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of histological diagnoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Clinical Pulmonary Infection Score (CPIS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: incidence of delta hemoglobin ≥ 30g/l
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Clinical response in avoiding bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: parasitological cure 24 hours after completion of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of occurrence of Grade 3 or higher adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and tolerability of Cu-64 SARTATE
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with PSA response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time to radiographic disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Beta-cell responsivity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: AUC from time 0 to the time of the last measurable drug concentration (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average plasma concentration at steady state (Cav,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first occurrence of microalbuminuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Development of enzymatic signs of myocardial injury or MI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fall/falls
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Tolerated Dose (MTD) of nivolumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of nivolumab and azacitidine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SNOT-22 Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Detection of infarction of the middle cerebral artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Classification of carotid plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of Patients With Atrial Arrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Patients With Delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Patient reported hip pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of in-patient hospital admissions 1 year after return of results
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Final Patient Pediatric Quality of Life (Peds QL) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Final Caregiver QoL score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Use of supplemental analgesics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Residual limb volume changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in disease compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in psychiatric symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in dyadic adjustment
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Unified Parkinson's Disease Rating Scale (UPDRS) Part III
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Absolute change in inflammatory lesion count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute change in non-inflammatory lesion count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with at least a 2 grade reduction in Evaluator's Global Severity Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Maximum Change from Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients with a BCVA Improvement of ≥15 Letters in the Study Eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Change from Baseline in BCVA in the Study Eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SIMPLICITY Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: International Knee Documentation Committee Subjective Score (IKDC)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: International Knee Documentation Committee Objective Score (IKDC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retreatment or rescue administered for IOP
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Ocular Itching at 16 Hours Duration of Action
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Cost Comparison
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total Time Comparison
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: oral health impact profile
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of samples matching final pathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical activity program attendance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Major objective response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain perception
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: High Sensitive C-Reactive Protein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reproducibility of HbA1C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to reach 100kcal/kg/d of enteral nutrition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight gain velocity during hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inducing or Boosting of a Cellular Immune Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: QOL score reduction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: 9-12 week continuous abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 9-26 week continuous abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Transient Neurologic Syndrome Incidence
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of postoperative wound drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence Rate of Adenomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence Rate of High-risk Adenomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence Rate of Colon Cancers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence Rate of Non-colonic Cancers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: success rate of spinal needle insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: success rate of single needle pass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percent Change in HPV Vaccine Initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pacing Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sensing Amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Adverse Events and Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Telemetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Immune Responses to Surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Successful Mobilization and Collection of PBSCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 6 minute walking distance (6MWD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change from baseline in ATP max
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in plate waste
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serving waste
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed concentration (Cmax) of CYP450 substrates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of CYP450 substrates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes